HPV Ends Here: Increasing Uptake of the HPV Vaccine

NCT06831929 | Recruiting

• 2 other identifiers: 2179292-11K01CA258956-01A1
• Study Type: interventional
• Target: 2,232
• Locations: 1 country
• Sites: 1

Brief Summary

Develop, implement, and evaluate a culturally tailored multilevel intervention to increase uptake of the HPV vaccine among eligible patients ages 10-12 of the University of California, Davis Health Community Physician (UCDH CP) primary care practices using a randomized controlled trial design.

Conditions

HPV Vaccine

Keywords

HPV; Human Papillomavirus

Outcome Measures

Primary Outcomes (1)

• Primary Outcome: Evaluation

  Number of participants who initiate and complete the HPV vaccine series

  One year

Study Arms (2)

Control Arm

NO INTERVENTION

These clinics will not receive any intervention and will continue with care as usual.

Intervention Arm

EXPERIMENTAL

These clinics will receive the multilevel intervention which will include tailored parent/patient education, appointment scheduling assistance, and primary care team trainings.

Behavioral: Intervention Arm

Interventions

Intervention Arm BEHAVIORAL

Within the intervention clinics, parents of patients between the ages of 10-12 (who are eligible for the HPV vaccine) will receive a culturally tailored customized HPV vaccine message and testimonial video from a patient/survivor of an HPV associated cancer (e.g., oropharyngeal, or cervical) via the MyChart patient portal. Parents will also receive a personal call from the research coordinator to remind them that their child is due for the HPV vaccine. If the parent is interested in scheduling the HPV vaccine appointment during this call, the research coordinator will transfer the parent to UC Davis appointment call center to schedule the appointment. Also, primary care team members will receive a semi-annual learn at lunch workshop focused on strategies to introduce the HPV vaccine to parents and how to address concerns from vaccine hesitant parents. Workshop content will be tailored/adapted to include patient/parent cultural considerations.

Intervention Arm

Eligibility Criteria

• Age: 10 Years - 12 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17)

You may qualify if:

• Clinic patients between the ages of 10-12 who are eligible for the HPV vaccine

You may not qualify if:

• Clinic patients who already received the HPV vaccine or with any contraindication to the HPV vaccine.

Sponsors & Collaborators

• University of California, Davis: lead
• National Cancer Institute (NCI): collaborator

Study Sites (1)

University of California Davis Health

Sacramento, California, 95817, United States

RECRUITING

Study Officials

• Julie HT Dang, PhD

  University of California, Davis

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Ramneek Kahlon, BS

CONTACT

9167312578; rkahlon@ucdavis.edu

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 6, 2025
• First Posted: February 18, 2025
• Study Start: February 28, 2025
• Primary Completion: January 31, 2026
• Study Completion (Estimated): December 31, 2026
• Last Updated: April 25, 2025

Record last verified: 2025-04

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)